Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective hoisted by Stifel Nicolaus from $200.00 to $207.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

ASND has been the subject of several other research reports. Oppenheimer reissued an “outperform” rating and set a $190.00 target price (up previously from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. StockNews.com lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Finally, Citigroup upped their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Trading Down 3.6 %

Shares of ASND opened at $122.00 on Friday. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The firm has a market capitalization of $7.40 billion, a P/E ratio of -15.10 and a beta of 0.66. The firm has a 50-day moving average price of $132.40 and a 200 day moving average price of $132.47.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Equities research analysts predict that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently modified their holdings of the stock. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $60,000. Price T Rowe Associates Inc. MD increased its position in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after purchasing an additional 234,446 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.